Brief: Tarsus Submits New Drug Application To The FDA For Tp-03 For The Treatment Of Demodex Blepharitis
07/09/2022 12:13
Sept 7 (Reuters) - Tarsus Pharmaceuticals Inc TARS.O :
* TARSUS SUBMITS NEW DRUG APPLICATION TO THE FDA FOR TP-03
FOR THE
TREATMENT OF DEMODEX BLEPHARITIS
Source text for Eikon: ID:nGNXbM26WT
Further company coverage: TARS.O
(Reporting by Pratik Jain)
((Pratik.Jain@thomsonreuters.com;))
Recent news on Tarsus Pharmaceuticals
See all newsBrief: Lisata Therapeutics Appoints Jeff Farrow To Board Of Directors
Brief: Tarsus Pharmaceuticals Files For Offering Of Up To 2.91 Million Shares Of Common Stock By Selling Stockholders
U.S. RESEARCH ROUNDUP-Argan, Mastec, Oracle
Tarsus Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Tarsus to expand eye disease pipeline with up to $800 million Alkeus acquisition (updated)